# Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

> **NCT05270044** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pierre Fabre Medicament** · enrollment: 815 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Encorafenib and Binimetinib
- **DRUG:** Placebo to match Encorafenib ; Placebo to match Binimetinib

## Key facts

- **NCT ID:** NCT05270044
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-02
- **Primary completion:** 2027-03-31
- **Final completion:** 2035-05-02
- **Target enrollment:** 815 (ESTIMATED)
- **Last updated:** 2023-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05270044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05270044, "Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05270044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*